Drug Safety Communications
This webpage was developed to provide the public with easy access to important drug safety information. The webpage contains the most recent Drug Safety Communications from FDA as well as links for Early Communications, Follow-Up Early Communications, Information for Healthcare Professional sheets, and Public Health Advisories issued prior to January 29th, 2010. You can also find drug specific information using the Index to Drug-Specific Information.
Starting July 18, 2011, you can find Spanish language versions of the Drug Safety Communications on our Drug Safety Communications in Spanish page.
El 18 de julio de 2011, se pueden encontrar versiones en español de las Comunicaciones de Seguridad de Medicamentos en nuestra Comunicaciones de la FDA sobre la seguridad de los medicamentos en español de la página.
您可以在我们《药品安全通讯》的中文网页上找到中文版的《药品安全通讯》。
Current Drug Safety Communications
- 3/31/2021 Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease
- 3/25/2021 FDA warns that abuse and misuse of the nasal decongestant propylhexedrine causes serious harm
- 2/4/2021 Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)
- 10/15/2020 FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid
- 9/24/2020 FDA warns about serious problems with high doses of the allergy medicine diphenhydramine (Benadryl)
Previous Drug Safety Communications
- 2021 Drug Safety Communications
- 2020 Drug Safety Communications
- 2019 Drug Safety Communications
- 2018 Drug Safety Communications
- 2017 Drug Safety Communications
- 2016 Drug Safety Communications
- 2015 Drug Safety Communications
- 2014 Drug Safety Communications
- 2013 Drug Safety Communications
- 2012 Drug Safety Communications
- 2011 Drug Safety Communications
- 2010 Drug Safety Communications
Resources For You
- CDER Conversation: CDER's Drug Safety Communications: Ensuring postmarket safety
- Index to Drug-Specific Information